← Leaderboards
Meredith A Morgan
University Of Michigan At Ann Arbor
$5,182,920
Attributed
$5,182,920
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,222,284 · 6
By mechanism
P50$6,729,407 · 2
R01$4,210,090 · 3
P30$282,787 · 1
Top collaborators
- Theodore S Lawrence3 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Yi Sun$9,791,676
- Mats Ljungman$9,091,730
- Ming Zhang$1,253,887
- Stephen Weiss$24,277,384
- Andrea Michelle Pesch$64,399
Others in their field
Top investigators on “Radiation”
- Philip J Disaia · University Of California Irvine$135,204,929
- Walter John Curran · Thomas Jefferson University$132,574,833
- Richard L Schilsky · University Of Chicago$122,521,723
- Polly Chang · Sri International$120,948,376
- Maury Tigner · Cornell University$104,613,212
- Norman Wolmark · Nsabp Foundation, Inc.$104,551,329
Research focus
RadiationTumorDna DamageMalignant Neoplasm Of PancreasNeoplastic CellResponseClinical TrialsDoseRadiation TherapyIn VivoMediatingFutureClinical ResearchTumor GrowthCellsPancreatic NeoplasmSurvival RatePathway InteractionsDna RepairImmune Checkpoint BlockadePreclinical StudyAdvanced Pancreatic CancerProgrammed Cell Death Ligand 1Pre-Clinical
Grant awards (20)
Molecularly Targeted Radiosensitization of Locally Advanced Cancers$2,027,150
P50 · FY2025 · CA
Project 1: Combining PARP inhibition with radiation to sensitize HR proficient pancreatic cancers to immunotherapy$236,326
P50 · FY2025 · CA · contact PI
Experimental Irradiation (EI)$96,030
P30 · FY2025 · CA · contact PI
Molecularly Targeted Radiosensitization of Locally Advanced Cancers$1,946,064
P50 · FY2024 · CA
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer$430,481
R01 · FY2024 · CA · contact PI
Project 1: Combining PARP inhibition with radiation to sensitize HR proficient pancreatic cancers to immunotherapy$226,873
P50 · FY2024 · CA · contact PI
Experimental Irradiation (EI)$92,372
P30 · FY2024 · CA · contact PI
Molecularly Targeted Radiosensitization of Locally Advanced Cancers$2,066,150
P50 · FY2023 · CA
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer$443,233
R01 · FY2023 · CA · contact PI
Project 1: Combining PARP inhibition with radiation to sensitize HR proficient pancreatic cancers to immunotherapy$226,844
P50 · FY2023 · CA · contact PI
Experimental Irradiation (EI)$94,385
P30 · FY2023 · CA · contact PI
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer$443,233
R01 · FY2022 · CA · contact PI
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer$452,277
R01 · FY2021 · CA · contact PI
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer$452,277
R01 · FY2020 · CA · contact PI
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2$368,125
R01 · FY2020 · CA · contact PI
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit$350,164
R01 · FY2016 · CA · contact PI
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit$347,032
R01 · FY2015 · CA · contact PI
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit$334,466
R01 · FY2014 · CA · contact PI
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit$285,608
R01 · FY2013 · CA · contact PI
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit$303,194
R01 · FY2012 · CA · contact PI